Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Jetstar to Charge for Overhead Cabin Bags From February 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Press release - No. 07 / 2018
Zealand Pharma to present at the Needham Healthcare Conference, March 27, 2018 in New York
Copenhagen, March 22, 2018 - Britt Meelby Jensen, President and Chief Executive Officer (CEO) of Zealand Pharma, will present at the 17th Annual Needham Healthcare Conference in New York, at the Westin Grand Central Hotel on Tuesday, March 27, 2018 at 10:00-10:30 am (EST).
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail: [email protected]
Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c2e28375-1185-4700-86f8-502d97a8bbe9
